Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report

Cureus. 2019 Dec 12;11(12):e6361. doi: 10.7759/cureus.6361.

Abstract

Metabolic disorders are characterized by pathologies like visceral adiposity, hypertension, type 2 diabetes mellitus (T2DM), dyslipidemia, impaired glucose tolerance, fatty liver, and so on, with insulin resistance being the main contributing factor. Insulin resistance and diabetes mellitus are commonly associated with elevated triglyceride levels. Among the available medications for treating metabolic disorders, only Saroglitazar has a dual peroxisome proliferator-activated receptor ɑ + γ action that can reduce high triglycerides and improve insulin sensitivity. This medication may also reduce liver fibrosis content. The present case report illustrates the efficacy of Saroglitazar in reducing hypertriglyceridemia and liver stiffness as assessed by shear wave elastography.

Keywords: hypertriglyceridemia; saroglitazar; shear wave elastography; type 2 diabetes mellitus.

Publication types

  • Case Reports